WO1991016338A1 - S-(lower fatty acid)-substituted glutathione derivative - Google Patents
S-(lower fatty acid)-substituted glutathione derivative Download PDFInfo
- Publication number
- WO1991016338A1 WO1991016338A1 PCT/JP1991/000581 JP9100581W WO9116338A1 WO 1991016338 A1 WO1991016338 A1 WO 1991016338A1 JP 9100581 W JP9100581 W JP 9100581W WO 9116338 A1 WO9116338 A1 WO 9116338A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glutathione
- compound
- group
- lower alkyl
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a novel and useful S-lower fatty acid glutathione derivative and a method for producing the same.
- the glutathione derivative has a platelet aggregation inhibitory action, an anti-inflammatory action, an anti-allergic action, an antitumor action, and a liver damage inhibitory action (particularly, Kaisho 6 3 — 8 3 3 7, Japanese Patent Application 1 — 7 9 9 5 6, Japanese Patent Application 1 — 1 8 3 4 8 4, Japanese Patent Application 1 — 2 5 1 5 3 4, Japanese Patent Application 1 2 5 6 3 7 0, Japanese Patent Application No. 2—3 6 7 4 5).
- the present inventors have searched for compounds having even more excellent medicinal effects, synthesized various novel glutathione derivatives, and sought to find out their medicinal effects together with the above-mentioned S- (2-carboxypropyl) glutathione.
- S- (2-carboxypropyl) glutathione, or glutathione or its ester can be added to acrylic acid, methacrylic acid, crotonic acid, gay cinnamate, etc., or to 3 unsaturated fatty acids or monochloroacetic acid.
- the inventors have found that the obtained compound or its salt has an excellent inhibitory effect on liver injury, and based on this new finding, completed the present invention.
- R represents a lower alkyl group which may be substituted, and 1 represents hydrogen.
- R .. represents hydrogen or an optionally substituted lower alkyl group, and represents a hydroxyl group or an optionally substituted lower alkoxy group.
- n indicates 1. Or a salt thereof, and
- R : 1 when R : 1 is a lower alkyl group, those having 1 to 10 carbon atoms are preferable.
- the alkyl group may be linear, branched, or cyclic, or may have a cyclic portion.
- n is 1 and represents hydrogen.
- R. Represents a lower alkoxy group, such as methoxy, ethoxyquin, propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy. Examples of the group include, but are not limited to, di-, n-pentyloxy, isopentyloxy, tert-pentyloxy, neopentyloxy, 2-methylbutoxy, 1,2-dimethylpropoxy, and 1-ethylpropoxy.
- the lower alkoxy group may contain a cyclic moiety such as a hydroxyl group or a fuunyl group.
- This compound may be used as the free acid or as a pharmacologically non-toxic salt, for example, an alkali metal salt such as a sodium or potassium salt, or an alkaline earth metal salt such as a calcium salt or a magnesium salt. It can.
- alkali metal salt such as a sodium or potassium salt
- alkaline earth metal salt such as a calcium salt or a magnesium salt. It can.
- These salts may be those in which all of the carboxy groups present in the present compound form a salt, or those in which a part thereof is in a salt form. All of them can be used appropriately for preparing the present drug.
- the compound of the present invention can be chemically synthesized as follows. Glutathione or its ester and the general formula
- Specific examples of the compound represented by the formula [ ⁇ ] include: acrylic acid, methacrylic acid, etc .; 5 unsaturated fatty acids and S-chloropropionic acid; 9 halogenated organic monocarboxylic acids. More specific Specifically, glutathione or guanoletathione monoester (7-glutamylcystinyl glycine ester) obtained by reacting glutathione with an alcohol corresponding to the target ester derivative in the presence of an acid such as sulfuric acid is converted to an aqueous solution or an aqueous solution.
- ⁇ , ⁇ unsaturated fatty acids such as acrylic acid and methacrylic acid, or / 3 halogenated organic monocarboxylic acids such as ⁇ -chloropropionic acid or esters or amides thereof, preferably ⁇ ⁇
- the reaction is carried out with stirring at about 4 to 8 at room temperature or under heating. This reaction is easily terminated.
- This reaction solution can be subjected to column chromatography or isolated and purified by recrystallization with an appropriate solvent to obtain the desired compound.
- Formulations containing the compound of the present invention effectively suppress the occurrence of acute and chronic liver injury, suppress the rise of GOT and GPT levels, are useful for the prevention and treatment of acute or chronic hepatitis, and are also useful for cirrhosis. It can also be used effectively for prevention and treatment of For example, it can be advantageously used for liver damage caused by drugs such as acetoaminophen.
- the preparation containing the compound of the present invention is appropriately used orally or parenterally as a liver damage inhibitor.
- any form such as tablets, granules, solid preparations of powders and capsules, and liquid preparations such as injections can be appropriately prepared according to the type of disease by a known method.
- These preparations usually contain binders, disintegrants, thickeners, dispersants, reabsorption enhancers, flavoring agents, buffers Excipients, surfactants, solubilizing agents, preservatives, emulsifiers, tonicity agents, stabilizers, and shaping agents such as pH adjusters may be used as appropriate.
- the dose of the active ingredient varies depending on the type of the compound, the type of the disease, the age of the patient, the weight, the dosage form, the indication, etc. In the case of oral administration, it is advisable to administer about 10 to 200 mg per day for adults several times a day.
- a drug containing the compound of the present invention may contain one or more of the present active ingredients in an appropriate combination, if necessary.
- Example 2 Using 4.0 g of glutathione monoisopropyl ester sulfate and 1.6 g of isobutyl methacrylate as in Example 1 (stirring was carried out for 48 hours), ethanol-ethyl acetate-petroleum benzene was used. Recrystallization affords 2.0 g of colorless amorphous crystals.
- the animals used were SD male rats (weighing about 180 g) purchased from the Shizuoka Experimental Animal Agriculture Cooperative. One hour after the test substance was orally administered (0.5 sole / kg), 300 mg / kg of acetaminofunne was intraperitoneally administered. Twenty-four hours later, blood was collected from the rat abdominal aorta to obtain serum. Soshi S-GOT and GPT were measured.
- the unit is IU / 11, bulging iMean soil S.E.
- the number of cases is 7 to 10, and the figures in parentheses indicate inhibition.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69122466T DE69122466T2 (de) | 1990-04-26 | 1991-04-26 | S-(niedere fettsäuren)-substituierte glutathionderivate |
JP3508262A JP2978562B2 (ja) | 1990-04-26 | 1991-04-26 | S―低級脂肪酸グルタチオン誘導体 |
EP91908790A EP0480071B1 (en) | 1990-04-26 | 1991-04-26 | S-(lower fatty acid)-substituted glutathione derivative |
KR1019910701528A KR970002905B1 (ko) | 1990-04-26 | 1991-04-26 | S-저급지방산 글루타티온 유도체 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11226090 | 1990-04-26 | ||
JP2/112260 | 1990-04-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991016338A1 true WO1991016338A1 (en) | 1991-10-31 |
Family
ID=14582257
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1991/000569 WO1991016065A1 (en) | 1990-04-26 | 1991-04-25 | Hepatic disorder inhibitor |
PCT/JP1991/000570 WO1991016337A1 (en) | 1990-04-26 | 1991-04-25 | S-(lower fatty acid)-substituted glutathione derivative |
PCT/JP1991/000581 WO1991016338A1 (en) | 1990-04-26 | 1991-04-26 | S-(lower fatty acid)-substituted glutathione derivative |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1991/000569 WO1991016065A1 (en) | 1990-04-26 | 1991-04-25 | Hepatic disorder inhibitor |
PCT/JP1991/000570 WO1991016337A1 (en) | 1990-04-26 | 1991-04-25 | S-(lower fatty acid)-substituted glutathione derivative |
Country Status (10)
Country | Link |
---|---|
US (2) | US5232913A (ja) |
EP (3) | EP0480060B1 (ja) |
KR (3) | KR970002904B1 (ja) |
AT (3) | ATE145919T1 (ja) |
CA (2) | CA2060209A1 (ja) |
DE (3) | DE69123428T2 (ja) |
ES (3) | ES2095317T3 (ja) |
RU (1) | RU2046798C1 (ja) |
TW (1) | TW203060B (ja) |
WO (3) | WO1991016065A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010138126A (ja) * | 2008-12-12 | 2010-06-24 | Sumitomo Chemical Co Ltd | N,S−ジ−tert−ブトキシカルボニルグルタチオン蛍光誘導体及びそれを中間体として用いるグルタチオン蛍光誘導体の製造方法 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6030950A (en) * | 1987-07-09 | 2000-02-29 | Ohlenschlaeger; Gerhard | Pharmaceutical therapeutic use of glutathione derivative |
US5599903A (en) * | 1992-04-03 | 1997-02-04 | Terrapin Technologies, Inc. | Glutathione analogs and paralog panels comprising glutathione mimics |
US5679643A (en) * | 1987-10-13 | 1997-10-21 | Terrapin Technologies, Inc. | Glutathione analogs and paralog panels comprising glutathione mimics |
KR970001509B1 (ko) * | 1990-02-17 | 1997-02-11 | 센쥬세이야꾸 가부시끼가이샤 | 글루타티온 유도체 |
US5786336A (en) * | 1991-04-29 | 1998-07-28 | Terrapin Technologies, Inc. | Target-selective protocols based on mimics |
US5955432A (en) * | 1992-04-03 | 1999-09-21 | Terrapin Technologies, Inc. | Metabolic effects of certain glutathione analogs |
TW225992B (ja) * | 1992-07-17 | 1994-07-01 | Senju Pharma Co | |
US5427425A (en) * | 1994-08-05 | 1995-06-27 | Droesch; Joaquin C. | Pickup tailgate mounting assembly |
ES2147162B1 (es) | 1999-01-27 | 2001-03-16 | Lacer Sa | "s-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias". |
US6596870B2 (en) | 2000-07-13 | 2003-07-22 | Brandeis University | Asymmetric synthetic methods based on phase transfer catalysis |
US7172905B2 (en) * | 2001-08-07 | 2007-02-06 | The University Of Chicago | Polypeptide immobilization |
WO2004005918A2 (en) * | 2002-07-05 | 2004-01-15 | University Of Chicago | Characterization of biochips containing self-assembled monolayers with maldi-tof-ms |
US20100021398A1 (en) * | 2008-01-18 | 2010-01-28 | Skinner Keith K | Compositions and methods for lightening skin and protecting skin from ultraviolet radiation with glutathione |
EP2295137B1 (en) * | 2008-05-28 | 2012-06-06 | Nagoya City University | Process for producing colloidal crystal |
US20130209366A1 (en) * | 2010-08-24 | 2013-08-15 | Oklahoma Medical Research Foundation | Glutathione-Lanthionine Compounds and Methods Related Thereto |
US9676818B2 (en) | 2013-01-17 | 2017-06-13 | University Of Kansas | Toll-like receptor 2-agonistic lipopeptides, and method of making the same |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60123497A (ja) * | 1983-12-02 | 1985-07-02 | コ−ネル・リサ−チ・フアウンデ−シヨン,インコ−ポレイテツド | グルタチオン伝達系 |
JPS60237963A (ja) * | 1984-05-02 | 1985-11-26 | Ajinomoto Co Inc | こく味調味料またはこく味の増強された食品の製造法 |
JPS61249958A (ja) * | 1985-04-19 | 1986-11-07 | スミスクライン・ベツクマン・コ−ポレイシヨン | ロイコトリエン拮抗物質 |
JPH02500841A (ja) * | 1987-07-09 | 1990-03-22 | オーレンシュレガー,ゲールハルト | グルタチオン誘導体の薬物治療的用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60104018A (ja) * | 1983-11-11 | 1985-06-08 | Kyowa Hakko Kogyo Co Ltd | Ν−メチルホルムアミド肝毒性の軽減剤 |
US4879370A (en) * | 1983-12-02 | 1989-11-07 | Cornell Research Foundation, Inc. | Glutathione delivery system |
JPS61249997A (ja) * | 1985-04-22 | 1986-11-07 | コ−ネル・リサ−チ・フアウンデ−シヨン・インコ−ポレイテツド | グルタチオンアルキルエステルおよびその用途 |
JPS638337A (ja) * | 1986-06-30 | 1988-01-14 | Senjiyu Seiyaku Kk | 抗血液凝固剤 |
DE3784905T2 (de) * | 1986-07-07 | 1993-08-05 | Teijin Ltd | Gamma-l-glutamyl-l-cysteinethylester und arzneimittel, die dieses als aktives mittel enthalten. |
JPS6463525A (en) * | 1987-05-08 | 1989-03-09 | Yamanouchi Pharma Co Ltd | Alcoholic liver triglyceride increase-suppressing agent |
JPH02255624A (ja) * | 1989-03-29 | 1990-10-16 | Senjiyu Seiyaku Kk | 血小板凝集抑制剤 |
US5102871A (en) * | 1989-04-24 | 1992-04-07 | Kyowa Hakko Kogyo Co., Ltd. | Nutrient composition |
JP2815179B2 (ja) * | 1989-07-14 | 1998-10-27 | 千寿製薬株式会社 | 抗炎症および/または抗アレルギー剤 |
US5093478A (en) * | 1989-07-14 | 1992-03-03 | Cornell Research Foundation, Inc. | Preparing glutathione monoesters |
JP2919867B2 (ja) * | 1989-09-27 | 1999-07-19 | 千寿製薬株式会社 | 抗腫瘍剤 |
JP2919870B2 (ja) * | 1989-09-29 | 1999-07-19 | 千寿製薬株式会社 | 肝障害抑制剤 |
KR970001509B1 (ko) * | 1990-02-17 | 1997-02-11 | 센쥬세이야꾸 가부시끼가이샤 | 글루타티온 유도체 |
-
1991
- 1991-04-25 RU SU915011089A patent/RU2046798C1/ru active
- 1991-04-25 DE DE69123428T patent/DE69123428T2/de not_active Expired - Fee Related
- 1991-04-25 EP EP91908175A patent/EP0480060B1/en not_active Expired - Lifetime
- 1991-04-25 CA CA002060209A patent/CA2060209A1/en not_active Abandoned
- 1991-04-25 DE DE69122831T patent/DE69122831T2/de not_active Expired - Fee Related
- 1991-04-25 ES ES91908176T patent/ES2095317T3/es not_active Expired - Lifetime
- 1991-04-25 WO PCT/JP1991/000569 patent/WO1991016065A1/ja active IP Right Grant
- 1991-04-25 EP EP91908176A patent/EP0480061B1/en not_active Expired - Lifetime
- 1991-04-25 US US07/778,134 patent/US5232913A/en not_active Expired - Fee Related
- 1991-04-25 AT AT91908176T patent/ATE145919T1/de not_active IP Right Cessation
- 1991-04-25 AT AT91908175T patent/ATE144531T1/de not_active IP Right Cessation
- 1991-04-25 KR KR1019910701527A patent/KR970002904B1/ko not_active IP Right Cessation
- 1991-04-25 WO PCT/JP1991/000570 patent/WO1991016337A1/ja active IP Right Grant
- 1991-04-25 KR KR1019910701526A patent/KR970008108B1/ko not_active IP Right Cessation
- 1991-04-25 ES ES91908175T patent/ES2093098T3/es not_active Expired - Lifetime
- 1991-04-26 ES ES91908790T patent/ES2092565T3/es not_active Expired - Lifetime
- 1991-04-26 KR KR1019910701528A patent/KR970002905B1/ko not_active IP Right Cessation
- 1991-04-26 EP EP91908790A patent/EP0480071B1/en not_active Expired - Lifetime
- 1991-04-26 WO PCT/JP1991/000581 patent/WO1991016338A1/ja active IP Right Grant
- 1991-04-26 US US07/773,595 patent/US5274177A/en not_active Expired - Fee Related
- 1991-04-26 CA CA002060210A patent/CA2060210A1/en not_active Abandoned
- 1991-04-26 AT AT91908790T patent/ATE143670T1/de not_active IP Right Cessation
- 1991-04-26 DE DE69122466T patent/DE69122466T2/de not_active Expired - Fee Related
- 1991-05-01 TW TW080103419A patent/TW203060B/zh active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60123497A (ja) * | 1983-12-02 | 1985-07-02 | コ−ネル・リサ−チ・フアウンデ−シヨン,インコ−ポレイテツド | グルタチオン伝達系 |
JPS60237963A (ja) * | 1984-05-02 | 1985-11-26 | Ajinomoto Co Inc | こく味調味料またはこく味の増強された食品の製造法 |
JPS61249958A (ja) * | 1985-04-19 | 1986-11-07 | スミスクライン・ベツクマン・コ−ポレイシヨン | ロイコトリエン拮抗物質 |
JPH02500841A (ja) * | 1987-07-09 | 1990-03-22 | オーレンシュレガー,ゲールハルト | グルタチオン誘導体の薬物治療的用途 |
Non-Patent Citations (4)
Title |
---|
Anal. Biochem., Vol. 183, No. 1 (1989) LEESA J. DETERDING et al. "Fast atom bombardment and tandem mass spectrometry for structure determination of cystein, N-acetylcystein, and glutathione adducts of xenobiotics" pp. 94-107. * |
Biochem. J., Vol. 125, No. 1 (1971) T. W. SPEIR et al. "Conjugation of glutathione with unsaturated acyl thiol esters and the metabolic formation of S-carboxyalkylcysteins" pp. 267-273. * |
Br. J. Ind. Med., Vol. 32, No. 1 (1975) PHILIPPA M. EDWARDS "Neurotoxicity of acrylamide and its analogs and effects of these analogs and other agents on acrylamide neuropathy" pp. 31-38. * |
CHEMICAL ABSTRACTS, Vol. 56, No. 1, January 8, 1962 (08. 01. 62) (Columbus, Ohio, U.S.A.) WALTER G. TOEKELT, "New r-L-glutamyl peptides in onion (Allium cepa). III", Abstract No. 716f, Suomen Kemistilehti 34B, 53-54 (1961). * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010138126A (ja) * | 2008-12-12 | 2010-06-24 | Sumitomo Chemical Co Ltd | N,S−ジ−tert−ブトキシカルボニルグルタチオン蛍光誘導体及びそれを中間体として用いるグルタチオン蛍光誘導体の製造方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1991016338A1 (en) | S-(lower fatty acid)-substituted glutathione derivative | |
CA2259621C (en) | Isocoumarin derivatives and their use in medicines | |
RU2128160C1 (ru) | Трометаминная соль (+)-(s)-2-(3-бензоилфенил)пропионовой кислоты, способ ее получения, фармацевтическая композиция | |
GB2051779A (en) | Esters of acyl-carnitines | |
JPH02161A (ja) | アミノ酸から誘導される新規な光学異性体と、その製造方法と、その医薬への応用 | |
JP2921124B2 (ja) | 酸化型グルタチオンアルキルエステル | |
CA1189520A (fr) | Procede de preparation de nouveaux derives de l'acide 4-phenyl-4-oxo-2-butenoique et de leurs sels | |
EP0134179B1 (fr) | Nouveaux dérivés de l'acide 4-phényl 4-oxo-buten 2-oique, leur procédé de préparation, des médicaments et des compositions les renfermant | |
JPH03112933A (ja) | 抗腫瘍剤 | |
US5747521A (en) | N-cinnamoyl-2-methyl-5-methoxy-3-indoleacetic acid ester, and pharmaceutical preparation containing the same | |
JP2919870B2 (ja) | 肝障害抑制剤 | |
US5424292A (en) | 5-aminosalicylic acid derivatives for the therapy of chronic inflammatory bowel diseases | |
WO1992016496A1 (en) | N-[[4,5-dihydroxy- and 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracene-yl]carbonyl]amino acids useful in the therapy of osteoarticular affections | |
WO1990013557A1 (en) | New s-adenosylmethionine derivative | |
JP2978562B2 (ja) | S―低級脂肪酸グルタチオン誘導体 | |
GB2193210A (en) | Glycine derivatives | |
FR2515038A1 (fr) | A titre de medicaments, certains derives de l'acide 4-phenyl 4-oxo 2-butenoique et compositions les renfermant | |
US4867737A (en) | Derivatives of 4-phenyl-4-oxo-2-butenoic acid their preparation process, their use as medicaments and compositions containing them | |
JPS63502432A (ja) | アシル化シアナミド組成物 | |
JP3029867B2 (ja) | S―低級脂肪酸グルタチオン誘導体 | |
JPS6324498B2 (ja) | ||
US4870056A (en) | Acylated cyanamide composition | |
JPH0228575B2 (ja) | Kokanenzai | |
RU2019993C1 (ru) | Антигепатопатическая композиция | |
JPS61277650A (ja) | 7−オキソ−pgi2エフエドリン塩類似体,その製造方法および医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP KR SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2060210 Country of ref document: CA Ref document number: 1991908790 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1991908790 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1991908790 Country of ref document: EP |